19 March 2026

New oral option for psoriatic arthritis wins FDA nod

5 minute read

The FDA has approved Bristol Myers Squibb’s deucravacitinib for adults with active psoriatic arthritis, extending deucravacitinib beyond plaque psoriasis after positive phase 3 trial results.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Register for a new account

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

Billing Address

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

Processing...

New oral option for psoriatic arthritis wins FDA nod

GLP-1 RAs linked to lower PsA risk

Yay! You can now get abused by virtual patients too

Telehealth gets ‘national standards’. Just don’t ask who’s enforcing them

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Log in

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover